2-bromo-5-methoxy-3-methyl-phenylamine | 631910-82-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-bromo-5-methoxy-3-methyl-phenylamine
• 英文别名: 2-bromo-5-methoxy-3-methylaniline
• CAS: 631910-82-2
• 化学式: C₈H₁₀BrNO
• 分子量: 216.077
• InChiKey: STYOEGNLKFBNDA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-bromo-5-methoxy-3-methyl-phenylamine 、 频那醇硼烷 、 2-(二环己基膦基)联苯 在 palladium diacetate 三乙胺 作用下， 以 1,4-二氧六环 、 乙酸乙酯 为溶剂， 生成 5-methoxy-3-methyl-2-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenylamine
  参考文献：
  名称：

  Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions

  摘要：

  揭示了一种治疗急性或慢性疾病症状的方法，该方法通过补体级联的经典途径介导，包括向需要此类治疗的哺乳动物施用公式I的化合物的治疗有效量或其溶剂化合物、水合物或药用可接受盐；其中在规范中定义了R1、R2、R3、R4和R7，Z为SO或SO2，Ar为本文中定义的芳香族或杂环芳基。

  公开号：

  US20040009995A1
• 作为产物：
  描述：

  (2-bromo-5-methoxy-3-methyl-phenyl)-carbamic acid tert-butyl ester 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 2-bromo-5-methoxy-3-methyl-phenylamine
  参考文献：
  名称：

  Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions

  摘要：

  揭示了一种治疗急性或慢性疾病症状的方法，该方法通过补体级联的经典途径介导，包括向需要此类治疗的哺乳动物施用公式I的化合物的治疗有效量或其溶剂化合物、水合物或药用可接受盐；其中在规范中定义了R1、R2、R3、R4和R7，Z为SO或SO2，Ar为本文中定义的芳香族或杂环芳基。

  公开号：

  US20040009995A1

文献信息

• [EN] NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS<br/>[FR] NOUVELLES AMIDINES DE THIOPHENE, COMPOSITIONS DE CES AMIDINES ET PROCEDE POUR TRAITER DES MALADIES ET DES ETATS MEDIES PAR LE COMPLEMENT
  申请人：DIMENSIONAL PHARM INC

  公开号：WO2003099805A1

  公开（公告）日：2003-12-04

  Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula (I) or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4 and R7 are defined in the specification, Z is SO or SO2, and Ar is an aromatic or heteroaromatic group as defined herein.

  揭示了一种治疗急性或慢性疾病症状的方法，该方法通过补体级联的经典途径介导，包括向需要此类治疗的哺乳动物施用化合物I的治疗有效量或其溶剂化合物、水合物或药用可接受盐；其中规范中定义了R1、R2、R3、R4和R7，Z为SO或SO2，Ar为本规范中定义的芳香族或杂环芳基。
• [EN] CINNOLINE DERIVATIVES AS AS BTK INHIBITORS<br/>[FR] DÉRIVÉS DE CINNOLINE EN TANT QU'EN TANT QU'INHIBITEURS DE LA BTK
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2013148603A1

  公开（公告）日：2013-10-03

  Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and R5 are defined in the specification. The compounds are inhibitors of Bruton's tyrosine kinase (BTK). This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders or conditions associated with BTK.

  公开的是Formula 1的化合物及其药学上可接受的盐，其中R1、R2、R3、R4和R5在规范中有定义。这些化合物是Bruton酪氨酸激酶（BTK）的抑制剂。本公开还涉及制备Formula 1化合物的材料和方法，包括含有它们的药物组合物，以及它们用于治疗与BTK相关的疾病、疾病或症状的用途。
• TETRAZOLINONE COMPOUNDS AND APPLICATIONS THEREOF
  申请人：SUMITOMO CHEMICAL COMPANY, LIMITED

  公开号：US20160150787A1

  公开（公告）日：2016-06-02

  A tetrazolinone compound represented by formula (1): wherein Q represents a 6-membered aromatic heterocyclic group optionally having one or more atoms or groups selected from Group P 1 , provided that a heteroatom constituting the heterocyclic group is a nitrogen atom, and the number of nitrogen atom is 1, 2, or 3; R 1 , R 2 , R 3 , and R 11 each represents a C1-C6 alkyl group optionally having one or more atoms or groups selected from Group P 2 ; R 4 and R 5 each represents a hydrogen atom, etc.; R 6 represents a C1-C6 alkyl group optionally having one or more halogen atoms, etc.; R 7 , R 8 , and R 9 each represents a hydrogen atom, etc.; and X represents an oxygen atom or a sulfur atom, has excellent control activity against pests.

  一种由式（1）表示的四唑酮化合物：其中Q代表一个6元芳香杂环基，可选地具有来自P1组的一个或多个原子或基团，前提是构成杂环基的杂原子为氮原子，且氮原子的数量为1、2或3；R1、R2、R3和R11分别代表一个C1-C6烷基基团，可选地具有来自P2组的一个或多个原子或基团；R4和R5各代表一个氢原子，等等；R6代表一个C1-C6烷基基团，可选地具有一个或多个卤原子，等等；R7、R8和R9各代表一个氢原子，等等；X代表一个氧原子或硫原子，对害虫具有出色的控制活性。
• Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
  申请人：3-Dimensional Pharmaceuticals, Inc.

  公开号：US07138530B2

  公开（公告）日：2006-11-21

  Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula (I) or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4 and R7 are defined in the specification, Z is SO or SO2, and Ar is an aromatic or heteroaromatic group as defined herein.

  本发明揭示了一种治疗由补体级联反应的经典途径介导的急性或慢性疾病症状的方法，包括向需要此类治疗的哺乳动物施用公式（I）的化合物或其溶剂化物、水合物或药学上可接受的盐的治疗有效量；其中R1、R2、R3、R4和R7在规范中有定义，Z为SO或SO2，Ar为芳香或杂芳基，如规范中所定义。
• CINNOLINE DERIVATIVES
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US20150038510A1

  公开（公告）日：2015-02-05

  Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , R 4 , and R 5 are defined in the specification. The compounds are inhibitors of Bruton's tyrosine kinase (BTK). This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders or conditions associated with BTK.

  本发明涉及公式1的化合物及其药学上可接受的盐，其中R1、R2、R3、R4和R5在说明书中有定义。这些化合物是布鲁顿酪氨酸激酶（BTK）的抑制剂。本发明还涉及制备公式1化合物的材料和方法，包括含有它们的制药组合物，以及它们用于治疗与BTK相关的疾病、障碍或状况的用途。